DOV vs STRO · P/E 27, rev $7.75B vs rev $62.0M
Dover Corporation (DOV) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Dover Corporation (DOV) is a specialty industrial machinery company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported DOV revenue for 2024-12-31 was $7.75B. Net income was $2.70B. Revenue was up 0.8% from 2023-12-31 to 2024-12-31. DOV currently screens at market cap $28.92B and trailing P/E 26.8.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
DOV currently screens at market cap $28.92B and trailing P/E 26.8. STRO currently screens at market cap $470.8M.
Not investment advice. Open the DOV and STRO stock pages for the full models.
Not investment advice.